ArticleFrontiers in cellular and infection microbiology2025
Epidemiological shift and clinical characteristics of rhinovirus genotypes in acute respiratory tract infection cases in Kunming, China, from 2019 to 2023.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Broad-spectrum host-targeting antivirals for rhinovirus infections: mechanisms and future perspectives.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We aimed to investigate the impact of the coronavirus disease 2019 (COVID-19) outbreak on the genetic diversity and clinical severity of rhinovirus (RV) in acute respiratory tract infection (ARTI) cases in Kunming, China. Methods: A total of 25,769 patients with ARTI from September 1, 2019 to December 31, 2023 were enrolled. Patients with COVID-19 were excluded from the study. Nasopharyngeal swabs were collected and screened for RV using multiplex reverse transcription polymerase chain reaction. RV-positive samples underwent nested PCR targeting the VP4/VP2 region. The amplified products were sequenced for genotype identification. Results: A total of 1,017 RV-positive cases were identified (detection rate 3.95%; 1,017/25,769), and all three RV species-RV-A, RV-B, and RV-C-were detected; RV-A was the most prevalent. Overall, 128 distinct RV genotypes, 40 untyped strains, and 1 recombinant strain (A1B) were identified. The predominant genotypes differed between age groups: those <18 years were mainly infected with C-untyped, A36, and A12, whereas those ≥18 years had C1, B52, and A60. Among RV-positive cases, 42.97% were associated with lower respiratory tract infections (LRTI), mainly caused by RV-A and RV-C. RV-C was associated with higher C-reactive protein and procalcitonin. Co-occurrences were recorded in 24.98% (254/1,017) of RV-positive cases and were associated with prolonged hospitalization. RV exhibited no clear seasonal pattern; however, following the COVID-19 outbreak, RV-C was replaced by RV-A. Conclusions: RV remains endemic with significant genetic diversity in the region. The COVID-19 pandemic led to a notable shift in the dominant circulating species from RV-A to RV-C. Emerging mutant strains have contributed to increased disease severity. Both RV-C and RV-A contribute to LRTI in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.